|
28 April 2005
Auckland, New Zealand, 28 April 2005 – Genesis Research and Development Corporation Ltd (NZSX/ASX: GEN) advises that in accordance with NZSX Listing Rule 3.3.2, the closing date for director nominations is 5.00 pm on Thursday, 19 May 2005, in respect of the company's annual shareholders' meeting scheduled to be held in June 2005. Genesis Research and Development Corporation Limited will advise the date and location of the annual shareholders' meeting once those details are determined. About Genesis Founded in 1994, Genesis is a New Zealand-based biotechnology company. It has built a broad therapeutic development platform targeting immune disorders and cancer and is developing RNAi therapeutics for immune disorders. The company has an extensive patent portfolio. Collaborations are maintained with Amgen Inc. (Nasdaq:AMGN), Corixa Corporation (Nasdaq:CRXA), SR Pharma plc (AIM:SPA), Jurox Pty Ltd, and AgResearch. AgriGenesis Biosciences Ltd is a wholly owned subsidiary of Genesis that is focused on using key plant cell signalling genes – novel hormones and transcription factors – to control commercial traits including flowering control, cold tolerance, growth rates and cell-wall lignin and cellulose content in commercial species. It has developed comprehensive plant EST databases including the world’s largest EST database for commercial forestry species. It has commercial collaborations with Wrightson (NZSX: WRI), HortResearch, Landcare Research and ArborGen LLC. For more information, please visit www.genesis.co.nz and www.agrigenesis.co.nz Media contacts: Jim McLean, Chairman Genesis Research and Development Corporation Limited, +64 9 373 5600 |